Bodycote plc (LON:BOY)

Checkpoint Therapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,106	1,146	1,134	1,084	1,650	1,417
Market Cap Growth	-18.71%	1.04%	4.63%	-34.27%	16.43%	-21.57%
Enterprise Value	1,278	1,282	1,224	1,207	1,791	1,524
Last Close Price	6.27	6.11	5.54	5.13	7.54	6.29
PE Ratio	40.06	57.31	13.25	14.71	27.72	3542.07
Forward PE	13.05	12.54	11.66	13.61	19.60	20.50
PS Ratio	1.52	1.51	1.41	1.46	2.68	2.37
PB Ratio	1.73	1.71	1.43	1.39	2.41	2.08
P/TBV Ratio	3.25	3.31	2.48	2.49	4.55	3.97
P/FCF Ratio	15.71	13.89	9.65	12.65	16.63	17.43
P/OCF Ratio	7.54	7.51	5.92	7.59	11.43	10.19
PEG Ratio	2.50	0.08	0.08	0.08	0.13	0.14
EV/Sales Ratio	1.76	1.69	1.53	1.62	2.91	2.55
EV/EBITDA Ratio	7.02	7.11	6.69	7.11	11.90	10.83
EV/EBIT Ratio	12.59	11.62	10.61	12.04	21.78	23.20
EV/FCF Ratio	18.15	15.54	10.42	14.08	18.05	18.75
Debt / Equity Ratio	0.30	0.23	0.12	0.18	0.23	0.19
Debt / EBITDA Ratio	1.05	0.78	0.49	0.75	0.95	0.83
Debt / FCF Ratio	2.71	1.83	0.83	1.60	1.58	1.58
Asset Turnover	0.67	0.69	0.70	0.67	0.56	0.56
Inventory Turnover	21.61	22.49	24.24	27.44	30.53	34.81
Quick Ratio	0.59	0.55	0.87	0.79	0.64	0.54
Current Ratio	0.74	0.68	1.05	0.94	0.75	0.63
Return on Equity (ROE)	4.17%	2.83%	11.03%	10.13%	8.78%	0.11%
Return on Assets (ROA)	5.81%	6.25%	6.26%	5.60%	4.71%	3.84%
Return on Capital (ROIC)	7.31%	8.06%	7.98%	7.11%	6.22%	5.14%
Return on Capital Employed (ROCE)	13.70%	14.20%	12.70%	11.10%	10.20%	8.10%
Earnings Yield	2.57%	1.75%	7.55%	6.80%	3.61%	0.03%
FCF Yield	6.37%	7.20%	10.36%	7.90%	6.01%	5.74%
Dividend Yield	3.67%	3.76%	4.10%	4.16%	2.65%	3.08%
Payout Ratio	145.77%	214.00%	47.43%	52.24%	82.35%	6275.00%
Buyback Yield / Dilution	4.15%	2.10%	0.25%	-0.23%	-0.29%	0.18%
Total Shareholder Return	7.82%	5.86%	4.34%	3.93%	2.37%	3.26%

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.